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ABSTRACT 
Title: Utility of Chemoport in Paediatric Oncological patients, a surgical perspective. 
Department: Department of Paediatric Surgery, Christian Medical College and 
Hospital, Vellore, Tamil Nadu, India-632004. 
Name of the Candidate: Dr. Nijagal Mutt.J.B.  
Degree and Subject: M.Ch. Paediatric Surgery 
Name of the Guide: Dr John Mathai. 
Aim/Objectives:  
To assess the utilization, indications for insertion, removal and risk factors 
responsible for the premature removal of the chemoports. 
Materials and Methods:  
All children who underwent chemoport insertion between January 2007 and 
December 2013 were included in this study. This was a retrospective study. The details of 
eligible patient were obtained from the clinical work station and centenary block 
operation register. Data were analysed using 2*2 tables for odd’s ratio and chi square test 
was employed to know the significance of the risk factors with the use of SPSS software 
version 1.6. 
Results:  
239 children were studied for the period between January 2007- December 2013. 
69 of the children had completed treatment, 97 were still undergoing chemotherapy, 32 
had complications like infection, thrombosis, extravasation, broken catheter and 
hematoma, deaths were seen in 17 children with chemoport in situ and 24 were lost to 
follow up. The median duration for which chemoport remained in situ including those 
with complications was 273 days. Amongst the risk factors leading to  premature removal 
of the chemoport studied namely; pre insertion chemotherapy, duration of surgery, 
seniority of the surgeon, serum albumin, prothrombin time, INR, Platelet count, total 
count and absolute neutrophil count at insertion. Absolute neutrophil count was the sole 
factor that reached statistical significance with a P value of 0.03. 
Conclusion:  
Chemoport is a good tool for vascular access in  paediatric cancer patients 
requiring long term chemotherapy Chemoports are not without complications. The most 
common complications are infectious complications amounting to 10.87% of our study 
population. Absolute neutrophil count <500 cells/microlitre is a strong predictor of 
complications with chemoport at any stage of chemotherapy.  
Key words: Chemoport, thrombosis, infection, absolute neutrophil count. 
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count and absolute neutrophil count at insertion. Absolute neutrophil count was the sole 
factor that reached statistical significance with a P value of 0.03. 
Conclusion:  
Chemoport is a good tool for vascular access in paediatric cancer patients 
requiring long term chemotherapy Chemoports are not without complications. The most 
common complications are infectious complications amounting to 10.87% of our study 
population. Absolute neutrophil count <500 cells/microlitre is a strong predictor of 
complications with chemoport at any stage of chemotherapy.  
Key words: Chemoport, thrombosis, infection, absolute neutrophil count. 
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INTRODUCTION 
 
A totally implantable access device or ‘chemoport’ is a small medical appliance that is 
installed beneath the skin. A catheter connects the port to a central vein with a large inflow of 
blood. Under the skin, the port has a septum through which drugs can be injected and blood 
samples can be drawn repeatedly, usually with far less discomfort for the patient than a more 
typical "needle stick". 
Ports are used mostly to treat oncology and hematology patients, but recently ports have 
been adapted also for hemodialysis patients. But, in our institute we use it for various paediatric 
oncological diseases. 
In this retrospective study, we try to study the number of patients who underwent 
chemoport insertions, the duration for which the chemoport was in situ and the number of 
patients who successfully completed chemotherapy. We have also tried to study the chemoport 
related complications and reasons for removal of the chemoports. 
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AIMS AND OBJECTIVES 
 
To study the utilisation of totally implanted devices or chemoports in paediatric 
oncology patients. 
The outcomes being studied were: 
A. Utilisation of totally implanted devices or chemoports in this services 
1. Number of ports inserted annually. 
2. Break down for insertion by oncological diagnosis.  
B. The Life  span of the ports: 
1. Duration for which port remains implanted. 
2. Number of successful completion of chemotherapy with ports. 
- Break down as per diagnosis. 
- Number still undergoing chemotherapy without complications. 
C. Chemoport intolerance and the identification of etiological association; 
1. Temporal relationship between occurrence of device intolerance and duration of 
chemotherapy.  
a. Number of days since insertion of device. 
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2. Cause for port complications. 
       a. Infectious. 
    i. Etiological agent and sensitivity pattern of isolates. 
    ii. Clinical syndrome of septic complication:  
                  Local infection: catheter tunnel/port pocket 
Systemic sepsis syndromes: Bacteremia/septic shock/MODS 
         b. Thrombosis. 
         c. Port Malfunction. 
Occlusion/disconnection/peripheral access failure/ extrusion/ fracture 
           d. Other reasons for adverse outcomes. 
i. Surgical complications at insertion. 
             ii. Complications at removal. 
3. Risk Factors for complication requiring removal. 
a. Insertion occurred at diagnosis or after administration of chemotherapy through 
peripheral access. 
b. Seniority of surgeon. 
c. Surgical procedure duration. 
d. White cell count/ ANC at insertion. 
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e. Albumin. 
 f. PT/ INR/ Platelets 
 
D. Port Removal 
 a. Number of chemoports removed.  
 b. Indication for removal. 
 c. Time since insertion. 
 d. Complication of removal.            
 E.     Framing of guidelines for best medical practice in our setup. 
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REVIEW OF LITERATURE 
The single most frequent operation that the surgeon performs for a child with 
malignancy, is for vascular access, for the administration of chemotherapy (1). 
Treatment of childhood malignancies has become more complex and 
sophisticated employing a multidisciplinary approach. It calls for repeated cycles of 
chemotherapy with the attended problems of systemic toxicities, immunosuppression and 
thrombosis which result in difficulties with venous access. As a consequence, centrally 
placed, long term venous catheters have gained widespread acceptance for the 
administration of chemotherapy, antibiotics, total parenteral nutrition, blood products and 
blood sampling, without causing much pain (2). 
There are two types of centrally placed long channels in use- 
1) Tunneled external catheter. 
2) Totally implantable access device or chemoport. 
Tunnelled external catheters are easy to access, less expensive, are associated 
with less extravasation into subcutaneous tissue. They allow for more rapid infusion and 
can be removed on an out patient basis without the need for anaesthesia. Totally 
implantable ports are more cosmetic, less prone to infection as they lie beneath the skin. 
They are low on maintainence and cause less restriction to physical activity.   
Even though they are generally considered safe and effective for the 
administration of chemotherapy, these devices are not without risks and complications. It 
has become the standard of care in many of the centres dealing with paediatric oncology 
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on a large scale. These long channels are prone to complications like dislodgement, 
thrombosis and infection (1, 2). However, the knowledge regarding the care and 
maintainence of these centrally placed lines has to be defined for each centre taking into 
consideration their unique situation.  
External Tunneled Catheters 
Historically, the first experience of the use of central venous access was by 
Dudrick and coworkers in 1968. A polyvinyl catheter was inserted into the external 
jugular vein which was then threaded into superior vena cava. But, the catheter was stiff 
and lead to significant thrombotic and infectious complications. The use of a more 
flexible silicone rubber catheter was reported by Broviac and coworkers in 1973. Silicone 
rubber leads to less thrombosis and is chemically inert. It was 90 cm long with a Dacron 
cuff which was 30 cm from the catheter hub. The catheter was tunneled subcutaneously 
from the site of venous access usually by a cephalic cut down onto the anterior chest wall 
and the cuff was placed proximal to the exit site. The vita cuff around the catheter 
promoted the fibrous tissue ingrowth and was believed to decrease the complications like 
infection and dislodgement of the catheter (2).  
Hickman and colleagues modified the design of catheters for the use in children 
undergoing bone marrow transplantation in 1979. Hickman’s catheter had a thicker wall 
and 0.1mm diameter more to allow for blood sampling as well as administration of 
chemotherapeutic agents. 
The success of the external tunneled catheters is well known and they are the most 
common form of vascular access in children. They can be single lumen or multiple lumen 
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external tunneled catheters. The sizes vary from 0.27F for premature neonates to 14F for 
older children. Painless access is the main advantage. However, they have several 
disadvantages when used for prolonged periods such as; altered body image, interference 
with play and leisure activities like swimming. In addition, they require periodic flushing 
and regular dressings. They are also prone to colonization by skin organisms and hence 
are not recommended for chemotherapeutic schedules lasting more than one month (3). 
Totally implanted Devices or chemoport 
A port consists of a reservoir compartment (the portal) that has a silicone 
diaphragm for needle insertion (the septum), with an attached tubing (the catheter) (4). 
The origin of the ports dates back to the attempts at using the existing devices from other 
specialities to provide venous access in cancer affected children. Hydrocephalic shunt 
was used for parenteral nutrition in an infant for a 22 month period by Belin and 
coworkers. Long term intrahepatic chemotherapy for unresectable hepatic tumour was 
devised by Fortner and Pahnke with the use of an Ommaya reservoir (2).  
The device is surgically inserted under the skin in the upper chest or in the arm 
and appears as a bump under the skin. It is completely internal and affords the patient 
considerable freedom to enjoy bath and pursue outdoor activities like swimming once the 
wound has healed. The catheter runs from the portal and is surgically inserted into a vein 
(usually the internal jugular vein in our institution). Ideally, the catheter terminates in the 
superior vena cava, just upstream of the right atrium. This position allows infused agents 
to rapidly reach all parts of the body (4). 
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The septum is made of a special self-sealing silicone rubber; it can be punctured 
hundreds of times before it weakens significantly. To administer treatment or to withdraw 
blood, a health professional will first locate the port and disinfect the area. Then he or she 
will access the port by puncturing the overlying skin with a 90° Huber point needle, 
although, a winged needle may also be used. (Due to its design, there is a very low 
infection risk, as the breach of skin integrity is never larger than the caliber of the needle. 
This gives it an advantage over indwelling lines such as the Hickman line). Negative 
pressure is created to withdraw blood into the syringe, to check for blood return and to 
see if the port is functioning normally. Next, the port will be flushed with a saline 
solution. 
Then, the treatment will begin. After each use, a heparin lock is made by injecting 
a small amount of heparinized saline into the device. This prevents development of clots 
within the port or catheter. In some catheter designs where there is a self-sealing valve at 
the far end, the system is locked with just saline. The port can be left unaccessed for as 
long as required. The port is covered in a dressing while in use to protect the site from 
infection and to secure the needle in position (4). 
Ports have many uses in cancer patients: 
- To deliver venoirritant chemotherapy to cancer patients who must undergo 
treatment frequently. Chemotherapy is often toxic, and can damage skin and muscle 
tissue, and therefore should not be allowed to extravasate into these tissues. Chemoports 
provide a solution for delivering drugs quickly and efficiently through the entire body via 
the circulatory system. 
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- To deliver total parenteral nutrition in those unable to take (adequate) food 
orally for a long period of time. 
- To deliver coagulation factors in patients with severe coagulopathy. 
- To withdraw (and/or return) blood in patients who require frequent blood tests. 
- To deliver antibiotics to patients requiring them for a long time or frequently. 
- For delivering radiopaque contrast agents, which enhance contrast in CT 
 imaging (4). 
Insertion techniques 
Selection of the vein for central venous access is dependent on the individual 
surgeon’s preferences. Most common veins used for vascular access are subclavian, 
external jugular and internal jugular vein. Alternative veins include the common femoral, 
the great saphenous vein, inferior epigastric vein and the inferior venacava through the 
trans lumbar and trans hepatic routes, the intercostals veins and the azygous vein (5-11). 
However, the requirement for a firm bony surface to place the reservoir precludes 
most of these options except for the large veins of the neck. 
Insertion in internal/external jugular vein 
Internal jugular vein lies on the lateral side of the triangle formed by the heads of 
the sternocleidomastoid muscle, just beneath the sternocleidomastoid muscle. The right 
internal jugular vein follows a straight path before entering the right atrium, while the left 
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enters the junction of the confluence of the subclavian and innominate veins at right 
angle. The external jugular vein makes an entry into the subclavian vein at a right angle 
which means the catheter must make an angle to enter the subclavian vein (2). 
Procedure is normally done in the operating room with general endotracheal 
anaesthesia. Fluoroscopy at the time of insertion is useful to confirm the position of the 
catheter. A roll is placed under the child’s shoulder and neck extended and turned 
towards the opposite side for adequate access to internal jugular vein/external jugular 
vein (IJV/EJV). The insertion can be done through percutaneous technique (Seldinger) as 
well as through a cut down technique for assessing IJV/EJV (2). An incision, midway 
between the clavicle and the ramus of the mandible is made and the vein is identified. A 
transverse incision is made in the chest away from the nipples and the port placed in the 
plane between the fascia and the muscles. It is fixed using non absorbable sutures. The 
catheter is tunneled subcutaneously into the neck on the lateral part of the incision made 
in the neck. In the case of EJV, proximal end can be ligated and the vein is assessed. If 
IJV is planned a venotomy is done and the catheter is introduced without the ligation of 
the proximal limb. The position of the catheter is confirmed using fluoroscopy. Skin 
incisions are closed using absorbable sutures. 
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Figure 1 Position of the child for chemoport insertion 
 
Figure 2 Isolation of Internal jugular vein 
 23 
 
Figure 3 Placement and fixation of the port in the chest 
 
Figure 4 Catheter introduction into the internal jugular vein 
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Figure 5 Confirmation of the position by fluoroscopy 
 
Figure 6 Post operative picture showing the port as a BUMP under the skin 
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Insertion in subclavian vein 
The position of the patient and the anaesthesia techniques remains the same as for 
IJV/EJV insertions. The subclavian vein is accessed via infraclavicular approach with an 
18G needle. Skin incision is made in the chest wall anteriorly and the catheter is tunneled 
subcutaneously into the exit of the guide wire which passes over the 18G needle and left 
in situ. The port is fixed through the lower incision and the catheter is trimmed to 
appropriate length and the position confirmed by fluoroscopy (12). 
Complications 
Complications with the chemoport can be classified into 
- intraoperative 
- post operative complications. 
Infection and occlusion are the most frequent complications associated with 
vascular access devices (VAD) (13). Extravasation, hydrothorax and cardiac perforation 
are less common complications but they are as serious as infections that lead to removal 
of the devices (14, 15, 16). 
Complications of the chemoport insertion can be varied from local infection to 
SIRS (requires its surgical removal) to a malposition when intraoperative imaging is not 
used. Other complications which can arise are; infection, thrombosis of the port, 
mechanical failure in which the system may break, pneumothorax and arterial injury 
which almost always compel its removal (1). Preset criteria for the diagnosis of device 
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related infections morbidity were defined using the following criteria: 1) a 10-fold or 
greater increase in colony forming units of organism per millimeter of blood obtained 
through the device, compared with simultaneous peripheral blood cultures 2) in the 
absence of peripheral blood cultures, more than 100 colony forming units of organism 
obtained through the device and 3) a positive result of catheter tip culture when the 
device was removed specifically for suspected device related infection, in the absence of 
cultures as stated above. Device related bactremia or fungemia was considered cured 
when culture results were negative at the termination of antibiotic therapy and no 
evidence of clinical infection occurred atleast 2 weeks later. Cutaneous site infection was 
defined as erythema, induration or tenderness and exudates at the catheter cutaneous port 
surface needle access site (17). 
Infection rates and definitions of catheter related infections are defined in 
different ways in different institutions. A study of 1100 central devices by Children 
Cancer Study Group noted 8.5%- 31% patients required removal because of infection 
(18). When the isolation of bacteria from two different sites as well as from the tip is 
same then it is defined as catheter related bacteremia (3, 19) 
The most common organism isolated from the catheter related infection is the 
coagulase negative staphylococci (CONS) (18). Other organisms which lead to catheter 
related infection are klebsiella pneumoniae, streptococcus viridans, group D 
Enterococcus, Staphylococcus aureus and Escherichia coli (20, 21). One of the ways to 
inhibit the bacterial colonization in the catheter is by modifications in the construction. 
Antibiotic bonding to the catheters have been shown to decrease the amount of 
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colonization (22). Skin entrance site of the catheter is believed to be the site of origin of 
catheter related infections. Bacteria multiply, advance along the catheter and finally gain 
access to the blood stream (23). 
Whenever there is a diagnosis of catheter related infection, controversy regarding 
keeping the catheter in situ or removal arise. Current recommendations include leaving 
the catheter in situ, antibiotic administration through the port and a repeat blood culture 
in 24-48 hours. Those who respond to this will be given therapy for 14-21 days. Those 
who do not respond require the removal of the catheter (3). 
Catheter related infections may not respond to antibiotic therapy because of the 
thrombus at the tip of the catheter where the bacteria or fungus colonize. If a thrombus is 
identified or suspected, a bolus of urokinase in normal saline should be infused through 
the catheter and repeated 24 hours later. Patients who fail to this therapy warrants 
removal of the catheter (24). 
The incidence of catheter related fungal infections was 2.7% from 43 cases 
studied in 11 various series. Candida tropicalis and albicans attach more extensively to 
polyvinyl chloride (PVC) in central catheters than to the peripheral lines which have 
Teflon. Treatment is amphotericin B and removal of the catheter (25, 26)  
Occlusion 
The common mechanical problem that occurs as a result of thrombus around the 
tip of the catheter, is the occlusion of the catheters. Others are, precipitation of poorly 
soluble fluid components (27) or an obstruction seen in the subclavian catheters near the 
level of the first rib. The placement of the thrombus at the right atrium not only affects 
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the catheter function but also attributes to complications such as clot dislodgement, 
pulmonary embolism and vessel thrombosis. Urokinase has been used to treat occlusion 
caused by thrombus in a variety of dosing regimens (28, 29, 30). 
A study on study of “Feasibility and Acceptability of Subcutaneous Implantable 
Ports in Cancer Patients” by Mittal L, Kalra M and Mahajan A in New Delhi observed 
complications like infection (4%), port fracture (4%), Thrombosis of the catheter (1%) 
and blockage in 1% of patients (31). 
There are various methods of maintainence of ports and tunneled catheters and 
have been individualized for each hospital. Care of the chemoport at home includes 
simple steps- Keep the site covered clamped and clean, changing the dressing every 7 
days. 
While accessing the port, simple steps should be followed like washing the hands 
with a sanitizer before accessing the port, cleaning the area of the port with an antiseptic 
solution, flushing before and after administration of the chemotherapy and putting a 
sterile dressing after the administration of the chemotherapy (3, 32). Reservoir accessed 
through the skin which can be painful and removal of the port requires an operative 
procedure which will subject the child to anaesthesia which are the main disadvantages. 
Low profile P.A.S port is an addition to the port which is placed in the forearm 
through basilic vein or cephalic vein. But, it has the disadvantage of being a very small 
port; it will be difficult to access in children with a lot of overlying soft tissue (2, 33). 
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Comparison of External tunneled catheters (EC) and chemoport (TID) 
Chemoports require less frequent cleaning, flushing and are subcutaneous and 
thus expect to be lower risk of complications when compared with ECs. Several studies 
have shown a significant lower infection rates with chemoports than ECs (34, 35). 
The Children Cancer Study Group review found that ECs were removed more 
frequently than chemoports for infection, but no data comparing the number of 
complications per catheter day of use were given (19). Comparison between EC and 
chemoports is difficult. Majority of the data implies that chemoport associated with less 
infection. But, ECs are inserted more frequently, which attribute to the higher rate of 
infection.  
Table 1  Advantages of EC versus chemoports (TIDs) (2) 
External tunnelled catheter Chemoports 
Easier to access Improved cosmetic result 
Less expensive than ports Less restriction to normal activities  
Pose less risk for extravasation into 
subcutaneous tissue 
Less maintainence care 
Allow more rapid infusion Well protected 
Can be removed at bedside Lower risk of infection 
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Patient and Family acceptance 
Acceptance of the family and the patient is an important aspect is deciding which 
vascular access device (VAD) to use. Questionnaires were obtained at 3 and 12 months 
post insertion by Poole and coworkers following insertion of external catheters (EC) and 
totally implanted devices (TID) or chemoports . There was a positive response to both EC 
and chemoport insertions. The only negative answers were regarding the daily change of 
dressing in the case of EC’s and the pain associated while accessing the chemoports. 
Even though patients experienced pain with chemoports, they strongly recommended 
chemoports as a vascular access for the administration of chemotherapy (2). 
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MATERIALS AND METHODS 
a. Inclusion criteria 
 All the children who underwent chemoport insertion between January 2007-
December 2013 in the Department of Paediatric Oncology will be included in the 
analysis. 
b.   Exclusion criteria 
 Children who underwent chemoport insertion elsewhere but taking chemotherapy in 
CMC hospital will be excluded. 
Historical: 
 Details regarding age, gender, diagnosis , date of insertion, duration of the 
chemoport in situ, date of removal, reasons of removals, seniority of the surgeon, 
duration of surgery and complications of the chemoport will be obtained from the 
Centenary Block Operating Room register, clinical work station and IP charts. 
Laboratory: 
 Total counts, Absolute neutrophil count, blood culture, catheter tip/pus culture, 
Prothrombin time, INR, serum albumin and platelet count reports will be obtained from 
the clinical work station.  
Outcomes measured:  
 Duration of the chemoport, the number of patients who successfully completed 
chemotherapy, complications of chemoport insertions, risk factors for chemoport related 
adverse events. 
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 Demographic details, oncological diagnosis, date of insertion and removal of 
chemoport will be obtained from the operation register maintained in the Centenary 
Block operating room in CMC Hospital, Vellore. All the details of chemotherapy 
completion, surgery details and the investigations will be obtained from the clinical work 
station. Adverse events will be obtained from the surgical and consultation records in 
clinical work station and IP records.   
 Odd’s ratio will be calculated in 2*2 tables. P value will be calculated using the chi 
square test to know the significance of the risk factors with the use of SPSS software 
version 1.6. 
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RESULTS AND ANALYSIS 
Figure 7 
Distribution of chemoport in our cohort 
 
In our cohort of 239 children, 101 had to be removed. Of these, there were a total 
of 69 who completed chemotherapy successfully with the chemoport in situ, 32 had 
complications with the chemoport in situ. 97 are undergoing chemotherapy, 17 deaths 
with chemoport in situ and 24 were lost to follow up after insertion of chemoport, at the 
end of the study as on 31/12/2013. 
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Table 2 
Age at Chemoport insertion  
Age Number of 
children 
<1yr 13 
1-6yrs 140 
6-12yrs 64 
>12yrs 22 
Total 239 
 
 
Youngest child in which chemoport was inserted was 21 days. Oldest child was 
17 years. 59% of the children were in the age group of 1-6 years and 5% of the children 
were less than 1 year. 
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Figure 8 
Gender composition of children undergoing chemoport insertion 
 
Total number of males were 148(62%) children and 91(38%) were females out of 239 
chemoport insertions. 
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Figure 9 
Yearly chemoport insertions 
 
 
There was a steady increase in the number of chemoport insertions from 2007- 
2008 with 67 of the chemoports out of 239 were inserted in the year 2013. 
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Figure 10 
Oncological diagnosis at insertion 
 
Majority of the chemoport insertions were done for lymphoproliferative disorders 
mainly leukemias amounting to 172 out of 239 children constituting 72%. Most common 
solid tumours for which chemoport was inserted were bone tumours and neuroblastoma. 
Solid tumours accounted for 66 out of 239 children who underwent chemoport insertions. 
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Table 3 
Duration of chemoport 
 
Duration (days) 
Successful 
performance of 
chemoport 
Complicated 
inclusive of  death 
with chemoport in 
situ 
Total 
<500 106* 32       (16) 154 
500-1000 41 2**      (1) 43 
1000-1500 18 - 18 
Total 165 50       (17) 215 
 
Note: Bold figure within brackets under the heading complications denote death 
* 1 child developed sepsis after the completion of chemotherapy. 
** Neck broken during the chemoport removal on table. 
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154, 43, and 18 children were in <500, 500-1000 and 1000-1500 days respectively with 
the port in situ.  The recorded number of days for which the chemoport was in situ ranged 
from 2 to 1461 days (mean 383.8 days). The shortest duration was 2 days (this patient 
was lost to follow up). Among those who successfully completed chemotherapy, the port 
was in situ between 77-1432 days (median 411.5 days). The median number of days for 
which the chemoport remained in situ including those who had complications was 
273 days.  
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Table 4 
Indications for removal of chemoport 
Indication Number 
Completed 68 * 
Septic complications 26 
Thrombosis 3 
Extravasation 1 
Neck broken 1 ** 
Hematoma 1 
Discontinued treatment 1 
Total 101 
 
* 1 child had sepsis after 6 days the completion of chemotherapy. 
** The neck broke at removal of chemoport after completion of chemotherapy. 
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Most common indication for the removal of the chemoport was completion of 
chemotherapy accounting to about 67%. The most frequent complication occurred was 
the infection in the form of local infection/ sepsis which occurred in 26% of patients that 
resulted in premature removal of the chemoport.  
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Table 5 
Infection leading to removal 
Type of infection Total number of children 
Local infection 11 
Sepsis 9(1-completed+sepsis) 
Local infection+sepsis 6 
Total 26 
 
Figure 11 Infection leading to removal 
 
n=26 
Local infection was seen in 11 out of 26 (42.4%) children and sepsis was seen in 
9 out of 26 (34.6%) children who had infection as an indication for removal. 6 out of 26 
(23%) children had local infection with sepsis which required chemoport removal. 
• Local infection was considered when there was erythema, induration, tenderness 
or discharge from the port insertion site. 
 
Local 
infection+
sepsis=6 
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Table 6 
Blood cultures before insertion 
Culture Total number of children 
Positive culture 5 
No growth 133 
Not done 95 
Contaminants 4 
Not known 1 
Total 239 
 
 
Positive cultures before insertion was seen in 2% of the children and 56% of the children 
had no growth on blood culture before the insertion of the chemoport. 
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Table 6(a) 
Blood culture Successful 
utilization of 
Complicated 
inclusive of death 
Total 
Culture positive 3 2 5 
Culture negative 71* 18 89 
Total 74 20 94 
 
* Included neck broken and 1 sepsis. 
On analyzing blood cultures before insertion, 5 were culture positive and 89 were 
culture negative among the total of 94 children. 3 were in the successful utilization of 
chemoport group and 2 were in the group of complications out of 5 children who had 
culture positive before insertion.  
71 (79.77%) were in the successful utilisation of chemoport group and 18 
(20.22%) were in the group with complications out of the 89 children who had culture 
negative before insertion. Odd’s ratio of 0.75 with a confidence interval between 0.36-
1.55 and P value was 0.29. 
 
 
 
 
 45 
Table 7 
Pattern of organism isolated during removal 
Organism Blood culture Pus/Catheter tip Culture 
Candida* 5 2 
Aspergillus* 1 1 
Staphylococcus aureus** - 2 
MRSA** 2 2 
Coagulase negative** 2 4 
Enterococcus** 1 1 
Enterobacter*** 0 2 
Pseudomonas*** 1 1 
Gram negative bacilli*** 2 4 
Contaminants 1 - 
No growth 9 10 
Not done 77 72 
Total 101 101 
 
* Fungal organisms *** Gram negative organisms ** Gram positive organism 
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Figure 12 Cultures at removal 
 
 
Out of 101 children, 29 children had pus/catheter tip culture and 24 children had 
blood culture done before the chemoport removal. 11 children had both blood culture and 
pus/cathteter tip culture out of which 5 had positive growth. 18 children had only 
pus/catheter tip culture and 11 had a positive pus/catheter tip culture. 13 children had 
only blood culture and 7 children had positive blood culture. 
 
 
 
 
 
 
5/11 
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Table 8 
Pre insertion chemotherapy 
Pre insertion 
chemotherapy 
Successful 
utilization of 
chemoport 
 
Complications 
 
Total 
Yes 122 35*         (12) 157 
No 43** 15            (5) 58 
Total 165 50          (17) 215 
 
Note: Bold figure within brackets under the heading complications denote death 
* The neck broke at removal of chemoport after completion of chemotherapy. 
** 1 child had sepsis after 6 days the completion of chemotherapy. 
24 were excluded from further analysis for the following reasons: 
* 14 children were lost to follow up and were excluded from the study. 
* 7 children were referred for chemotherapy and were excluded from the study. 
* 2 were discharged on request and were excluded from the study. 
* 1 child’s records could not be accessed as hospital number was not known and 
excluded from the study.  
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Chemoport was inserted after the initiation of chemotherapy in 157 children and 
58 children had chemoport inserted as soon as the diagnosis was made in 215 children. 
Out of 157 children who receieved chemotherapy before insertion, 122(77.70%) had 
completed or were still going on with chemotherapy and 35 (22.30%) had complications 
including death. 43 (74.1%) children completed chemotherapy or were undergoing 
chemotherapy and 15 (25.9%) children had complications including death out of 58 
children who did not receive chemotherapy before insertion. Odd’s ratio was 1.04 
(confidence interval between 0.8-1.2) with P value 0.58. 
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Table 9 
Seniority of the surgeon 
 
Seniority 
Successful 
utilization of 
chemoport 
Complicated 
inclusive of 
death with 
chemoport in 
situ 
Total 
Consultant 60* 26**  (7) 86 
Registrar 98 21     (9) 119 
Not known 7 3      (1) 10 
Total 165 50     (17) 215 
 
Note: Bold figure within brackets under the heading complications denote death 
* 1 child developed sepsis after the completion of chemotherapy. 
** Neck broken during the chemoport removal on table.  
All the chemoport insertion were done with consultant having scrubbed on the 
case. Out of 215 children, the primary surgeon in 86 was consultant (assistant professor 
and above), 119 was registrar and 10 were unknown as the theatre details were not 
available. 
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 60 (69.8%) children were in the completed and going on group and 26 (30.2%) 
were in the complicated which included death out of the 86 insertions done by 
consultants. 98 (82.4%) were in the completed and going on group and 21 (17.6%) were 
in the complicated which included death out of the 119 insertions done by registrars. 7 
(70%) were in the completed and going on group and 3 (30%) were in the complicated 
group out of the 8 for which operator was unknown. P value was calculated as  0.09 by 
chi square test. 
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Table 10 
Duration of surgery 
Duration of 
surgery 
Min 
Successful 
utilisation of the 
port 
Complicated 
inclusive of death 
with chemoport in 
situ 
Total 
<60 4 1 5 
60-120 136 35*     (14) 171 
>120 23** 13       (3) 36 
Not known 2 1 3 
Total 165 50       (17) 215 
 
Note: Bold figure within brackets under the heading complications denote death 
* Neck broken during the chemoport removal on table. 
** 1 child developed sepsis after the completion of chemotherapy. 
The median duration for the insertions was 100 min. Out of 215 children, 5 were 
less than 60 min, 171 were done between 60-120min, 36 were done in more than 120min 
and 3 were unknown as the theatre details were not available. There were no operative 
complications in the entire series. P value was calculated as 0.23 by chi square test. 
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Table 11  
Serum albumin at insertion 
 
Serum albumin at 
insertion g/dl 
Successful 
utilization of 
chemoport 
Complicated 
inclusive of death 
with chemoport in 
situ 
Total 
<3.5 14* 3  (1) 17 
3.5-5.0 72 21 (6) 93 
>5.0 3 1 4 
Not known 76 25** (10) 101 
Total 165 50  (17) 215 
 
Note: Bold figure within brackets under the heading complications denote death 
* 1 child developed sepsis after the completion of chemotherapy. 
** Neck broken during the chemoport removal on table. 
Serum albumin was studied as a nutritional marker. P value was calculated as  
0.92 by chi square test. Serum albumin did not show any statistical significance with the 
complications. 
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Table 12 
Prothrombim time (PT) at insertion 
 
PT at insertion sec 
Successful 
utilization of 
chemoport 
Complicated 
inclusive of death 
with chemoport in 
situ 
Total 
<10 6 2  (1) 8 
10-12.5 86 24* (9) 110 
>12.5 22** 8  (2) 30 
Not done 51 16 (5) 67 
Total 165 50  (17) 215 
 
Note: Bold figure within brackets under the heading complications denote death 
* Neck broken during the chemoport removal on table. 
** 1 child developed sepsis after the completion of chemotherapy. 
  PT was studied as a risk factor for complications. P value was calculated as 0.95 
by chi square test. PT was not statistically significant. 
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Table 13 
INR at insertion 
 
INR 
 
Successful 
utilization of 
chemoport 
Complicated 
inclusive of death 
with chemoport in 
situ 
Total 
<1 35 10   (4) 45 
1-1.25 73 22*  (8) 95 
>1.25 6** 2 8 
Not done 51 16   (5) 67 
Total 165 50    (17) 215 
 
Note: Bold figure within brackets under the heading complications denote death 
* 1 child developed sepsis after the completion of chemotherapy. 
** Neck broken during the chemoport removal on table. 
 INR was studied as a risk factor for complications. P value was calculated as 
0.997. INR was not statistically significant. 
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Table 14 
Platelets at insertion 
Platelets 
lakh/cumm 
Successful 
utilization of 
chemoport 
Complicated inclusive 
of death with 
chemoport in situ 
Total 
< 50000 65 * 21** (8) 86 
50000-100000 19 6  (4) 25 
>100000 81 23  (5) 104 
Total 165 50   (17) 215 
 
Note: Bold figure within brackets under the heading complications denote death. 
* 1 child developed sepsis after the completion of chemotherapy. 
** Neck broken during the chemoport removal on table. 
Platelet count was studied as a risk factor for complications. P value was 
calculated as 0.92 by chi square test. Platelets were not statistically significant. 
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Table 15 
Total count at insertion 
Total count 
Cells/cumm 
Successful utlisation of 
chemoport 
Complicated inclusive of 
death with chemoport in situ 
Total 
<4000 71 20 (6) 91 
4000-10000 54 15* (8) 69 
>10000 41** 14 (3) 55 
Total 165 50 (17) 215 
 
Note: Bold figure within brackets under the heading complications denote death 
* Neck broken during the chemoport removal on table. 
** 1 child developed sepsis after the completion of chemotherapy. 
Out of 215 insertions, 71 were successfully using their chemoport despite the total 
count being less than 4000 cells/cumm at insertion. Out of the 91 children with counts 
<4000 cells/cumm there were 20 complications inclusive of 6 deaths. The number of 
complications came down as the total count reached the normal values. 
P value was calculated as 0.86 by chi square test. 
 
 
 57 
Table 16 
Absolute neutrophil count (ANC) at insertion 
ANC 
cells/microlitre 
Successful 
utilization of 
the chemoport 
Complicated Odd’s ratio Total 
<500 66* 12     (4) 2.21 (1.03-5.0) 78 
500-1000 13 11** (4) 1.13 (0.5-2.25) 24 
1000-1500 11*** 4       (2) 1.07 (0.5-2.13) 15 
1500-2000 11 4       (2) 1.01 (0.4-2.05) 15 
>2000 62 19    (5) - 81 
Total 165 50    (17) - 215 
 
Note: Bold figure within brackets under the heading complications denote death 
*2 children differential counts could not be done as the total counts was less than 500. 
** Neck broken during the chemoport removal on table. 
*** 1 child developed sepsis after the completion of chemotherapy. 
Complications seems to be decreasing with increasing ANC more than 500 
cells/microlitre. P value was calculated as 0.03 by chi square test. 
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 Odd’s ratio was calculated at each level by merging the cells beyond each level. 
Odd’s ratio was 2.21 (confidence interval between 1.03-5.0 with a P value of 0.02) for 
ANC < 500 cells/microlitre. Odd’s ratio was statistically significant at ANC <500 
cells/microlitre at insertion. However, the Odd’s ratios beyond the ANC level of 500 
cells/microlitre were not significant.  
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Table 17 
Absolute neutrophil count (ANC) at removal 
ANC 
Cells/microlitre 
Completed Complicated Total 
<500 14* 21 35 
500-1000 2 1 3 
1000-1500 7 3 10 
1500-2000 4 1 5 
>2000(normal) 42 6** 48 
Total 69 32 101 
 
*1 child had sepsis after completion of chemotherapy. 
** 1 had neck broken at the time of chemoport removal. 
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Table 17(a) 
ANC at removal with complications 
ANC Infection Sepsis Haemotoma Thrombo
sis 
Extrav
asatio
Discontinue
d treatment 
Total 
<500 17 - 1 2 1 - 21 
500-
1000 
1 - - - - - 1 
1000-
1500 
2 - - - - 1 2 
1500-
2000 
1 - - - - - 1 
>200
0 
4 1 - 1 - 1 7 
Total 25 1 1 3 1 1 32 
 
There were totally 101 removals out of the 239 chemoport insertions. Most of 
these removals had complications which occurred at ANC <500 cells/microlitre. 
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Table 18 
Total Count (TC) at removal 
TC cells/cumm Completed Complicated Total 
<4000 23* 27 50 
4000-10000 42 3 45 
>10000 4** 2 6 
Total 69 32 101 
 
* 1 child had sepsis after completion of chemotherapy. 
** 1 child had neck broken during chemoport removal after completion of chemotherapy. 
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Table 18(a) 
TC at removal with complications 
TC  Infection Sepsis Hematoma Thrombosis Extravasation Discontinued 
treatment 
Total 
<4000 21 - 1 3 1 1 27 
4000-
10000 
2 1 - - - - 3 
>10000 2 - - - - - 2 
Total 25 1 1 3 1 1 32 
 
Most of the complications occurred at TC <4000 cells/cumm. 
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Table 19 
Platelets at removal 
Platelets 
lakh/cumm 
Completed Complicated Total 
<50000 9 15 24 
50000-1lakh 2 6 8 
>1lakh 58* 11 69 
Total 69 32 101 
 
* 1 child had sepsis after completion of chemotherapy and 1 had neck broken at the time 
of chemoport removal. 
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Table 19(a) 
Platelets at removal with complications 
Platelet 
count 
Infection Sepsis Hematoma  Thrombosis Extravasation Discontinuation 
of treatment 
Total 
<50000 13 - 1 1 - - 15 
50000- 
1 lakh 
4 1 - 1 - - 6 
>1 lakh 8 - - 1 1 1 11 
Total 25 1 1 3 1 1 32 
 
Infection was most common complication in platelets <50000 cells/cumm and 
only one child had a hematoma with platelets <50000cells/cumm. 
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Table 20 
In situ period of chemoport associated with complications  
Duration Infection Sepsis Thrombosis Hematoma Extravasation Total 
<6 weeks 6 - 1 1 - 8 
>6 weeks 19 1 2 - 1 23 
Total 25 1 3 1 1 31 
 
  6 weeks duration was taken as the cut off for early and late complications with the 
premise that complications occurring within 6 weeks would be related to the surgical 
procedure. 
Out of 31 complications for which chemoport were removed, 8 complications 
were seen in < 6 weeks and 23 complications were seen in > 6 weeks duration with 
chemoport. 6 children had infection, 1 had thrombosis and 1 had hematoma within 6 
weeks as the complication leading to removal of the port out of 31 children who had 
complications. 23 children had complications after 6 weeks. Infection was the most 
common complication during both time periods. 
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DISCUSSION 
The vascular access in paediatric oncology patients is required for a long duration 
and hence chemoports are used. In this study, we retrospectively studied the utilisation of 
chemoport and the associated morbidity in our centre. We also tried to identify the 
significant risk factors responsible for complications which resulted in the removal of the 
chemoport. This was done in order to draw the guidelines for best medical practice with 
respect to chemoports for our institution. 
There were a total of 239 chemoport insertions and 101 removals from January 
2007 to December 2013 in paediatric cohort at our centre. Most of the children were in 
the age group of 1-6 years constituting to about 59% (age range 21 days to 17 years) of 
the total insertions. There has been a steady increase in the number of chemoport 
insertions from 2007 to 2013 reflecting an increasing acceptability of the chemoports 
amongst the paediatric oncological patients. Currently, between 50 and 60 chemoports 
are inserted every year.  
Most of the children who had chemoport insertions had lymphoproliferative 
disorders mainly leukemias accounting for 172 (72%) out of 239 children. The solid 
tumours comprised the rest and the most common were bone tumours and neuroblastoma. 
The longest duration for which the chemoport was in situ was 1461 days and 
shortest was 2 days (Child was lost to follow up). The median duration of the 
chemoport remaining in situ in those who successfully completed chemotherapy was 
411.5 days. Children with AML, ALL require intensive chemotherapy for atleast 6 
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months. Hence, chemoport was inserted for the long term administration of 
chemotherapy.  
The indications for the removal (101 children) of the port in our cohort were 
completed chemotherapy (67%), infection (26%), thrombosis (3%), extravasation (1%), 
hematoma (1%), broken catheter (1%) and discontinued treatment (1%) as the tumour 
was resistant to chemotherapy. In this study, the most common indication for the removal 
of chemoport was completion of the chemotherapy. 
Complications resulted in the removal of chemoports before completion of the 
chemotherapy in 32 children accounting for 31.7% of the removals. The most common 
complication which lead to removal of the port was infection seen in 26 patients. Local 
infection defined as induration, erythema, discharge and tenderness was seen in 42.4%, 
sepsis was seen in 34.6% and 23% were having local infection and sepsis at the time of 
removal.  
60% were able to complete the chemotherapy or were undergoing chemotherapy 
with a positive culture before insertion and 79.77% were able to complete or were 
undergoing chemotherapy in the group of culture negative patients. Odd’s ratio was 
calculated to be 0.75 with a P value of 0.29 and found to be statistically insignificant.  
In our study, the most common isolate on blood culture was candida seen in 5 out 
of 29 patients and coagulase negative staphylococci and gram negative bacilli were the 
most common organism on pus/catheter tip culture seen in 4 out of the 32 chemoport 
removals which were removed for various complications. Other organisms were MRSA, 
enterobacter, enterococcus, pseudomonas, staphylococcus and aspergillus species. 
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Overall, various staphylococci including MRSA was the most common isolate in those 
with infection. 
An attempt was made to identify the risk factors resulting in the complications 
that lead to the removal of the port. The risk factors studied were pre insertion 
chemotherapy, duration of surgery, seniority of the surgeon, serum albumin, PT, INR, 
platelet count, total count and absolute neutrophil count. 
Table 21 Odd’s ratio and P value for risk factors studied 
Risk factor Odd’s ratio/Chi square 
value 
P value 
Pre insertion chemotherapy 1.04 (0.8-1.2)* 0.58 
Seniority of the surgeon 4.6978** 0.09 
Duration of surgery 4.2785** 0.23 
Serum albumin at insertion 0.457** 0.92 
Prothrombin time at insertion 0.3512** 0.95 
INR 0.0557** 0.997 
Platelet count at insertion 0.1487** 0.92 
Total count at insertion 0.2993** 0.86 
Absolute neutrophil count <500 
cells/cumm at insertion 
2.21 (1.03-5.0)* 0.02 
 
* Odd’s ratio      ** chi square value 
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The significant risk factor identified was absolute neutrophil count (ANC). It 
seemed to support the hypothesis that as immunity fell, propensity for infection increases. 
On studying various levels of absolute neutrophil count, it was noted that a statistically 
significant rise in complication was present with absolute neutrophil count <500 
cells/microlitre. 
Table 22  
Odd’s ratio at various levels for absolute neutrophil count (ANC) 
ANC 
cells/microlitre 
Successful 
utilization of 
the chemoport 
Complicated Odd’s ratio Total 
<500 66* 12    (4) 2.21 (1.03-5.0) 78 
500-1000 13 11** (4) 1.13 (0.5-2.25) 24 
1000-1500 11*** 4     (2) 1.07 (0.5-2.13) 15 
1500-2000 11 4      (2) 1.01 (0.4-2.05) 15 
>2000 62 19    (5) - 81 
Total 165 50    (17) - 215 
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Moreover, this table seems to suggest a dose related inverse relationship 
between ANC and complication. However, statistical significance could not be 
demonstrated at each level. 
   ANC dropping during chemotherapy was also associated with greater risk of 
complications. 21 out of 32 (65%) children had complications with ANC <500 
cells/microlitre. All these seem to suggest that neutropenia precludes longevity of the 
chemoport remaining in situ. 
 It is of interest that children with thrombocytopenia <50000 cells/cumm in our 
cohort had more complications. However, there were only 4 thrombotic and hemorrhagic 
complications noted in the entire 32 children with complication which lead to chemoport 
removal (1 thrombotic and 1 hematoma in <50000 cells/cumm). The neutropenia and 
thrombocytopenia seemed to point myelosuppression as the common culprit.  
 Complications were studied with respect to time of occurrence since insertion. A 
time period of 6 weeks following insertion was chosen to identify surgery related 
complications. The most common complication which occurred at a duration of < 6 
weeks from the time since insertion of the port was infection seen 6 out of the 8 patients. 
The other complications seen were thrombosis in 1 child and hematoma in the other.  
The most common complication which occurred after 6 weeks following the 
insertion of the chemoport was infection seen in 20 out of the 23 children. Other 
complications which were seen after 6 weeks of insertion of the chemoport were 
thrombosis in 2 children and extravasation in one. Most complications occurred after 6 
weeks. 
 71 
CONCLUSION 
• Chemoport is a good tool for vascular access in cancer requiring long term 
chemotherapy. 
• Chemoports are not without complications. The most common 
 complications are infectious complications amounting to 10.87%.  
• Absolute neutrophil count <500 cells/microlitre is a strong predictor of 
complications with chemoport at any stage of chemotherapy. 
• The common isolates are staphylococci and fungi and appropriate empiric 
antibiotics depending on the local sensitivity pattern should be employed in 
sepsis. 
• Surgical complications were minimal and not related to the 
 Seniority of the primary surgeon or duration of surgery in our cohort. 
• With proper maintainence and care of the port, it can be used   
 safely as a vascular portal for administration of chemotherapy for prolonged 
periods of time.  
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RECOMMENDATIONS 
• Absolute neutrophil count seems to be a contraindication for the insertion of 
chemoport. 
• Efforts to maintain absolute neutrophil count >500 cells needs to be studied and 
employed in the clinical setting. 
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PROFORMA FOR THE CHEMOPORT STUDY 
 
Unique identification number 
 
Hospital number 
 
Name        Age  
 
Gender 
 
Oncological diagnosis 
 
Surgical details: 
 
Date of insertion       Seniority of surgeon  
 
Duration of surgery  
 
Investigations at insertion: 
 
PT      Albumin 
 
Platelets     INR 
 
White cell count    ANC  
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Date of adverse event 
 
Date of removal 
 
Duration of chemoport 
 
Reason for removal 
 
Adverse events- Y/N 
If yes Thrombosis, infection, cutaneous site infection, systemic complication- 
 
Investigations at the time of removal for complications- 
 
Total counts 
 
ANC 
 
Blood culture 
 
Catheter tip culture/pus culture 
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Format for Informed Consent Form for Subjects 
Informed Consent form to participate in a research study 
 
Study Title: Utility of chemoport in Paediatric Oncological patients, a surgical 
perspective 
Subject’s Initials: __________________  
Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
(Subject) 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask questions.  
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected.  
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published.  
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(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). 
(v)  I agree to take part in the above study.  
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
 
Signatory’s Name: _________________________________         Signature:  
Or 
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
 81 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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Sl 
No Age Sex Diagnosis Indication 
Insertion 
TC 
PT 
insertion  Platelets 
Blood 
cultures Chemo 
Duration 
port 
ANC 
removal 
TC 
removal  
Platelets 
removal 
Blood Cul 
removal 
Pus/Catheter 
culrem rem 
Duration 
of 
surgery Seniority  
ANC at 
insertion 
ser alb 
insertion Without port 
INR 
insertion 
1 2 F Medulloblastoma infection 11100 10.5 498000 N N 102 28 1400 19000 candida E Coli 1:30(90) S 3850 4.8 completed 0.97 
2 3 M ALL infection 39300  72000 N Y 291 1632 3400 282000 candida No growth 1:45(105) S 1556  completed  
3 2 M ALL completed 5800  374000 N N 321 52 1300 117000   1:40(100) S 1740    
4 1 M ALL completed 1500  22000 N Y 1072 1275 2500 184000  No growth 1:30(90) S 30 3.9   
5 1 F Pre B ALL completed 30800  12000 No growth Y 1114 6336 9900    2:00(120) S 567 4.4   
6 3 f ALL  9200  196000  N 796      1:25(85) S 3220  death  
7 10 M ALL completed 4700  236000 N N 1432 3104 9700 165000   1:45(105)  1271 4.2   
8 10 F Osteosarcoma                   
9 3 F Pre B ALL  1500 10.8 225000 no growth Y 195      1:40(100) S 75 4 
don’t know 
referred 0.93 
10 2 F Pre B ALL completed 4200 11.4 344000 N N 271 
Not 
done 300 71000 Coag nega  2:00(120) S 1638   1.04 
11 12 M PNET completed 11800 clot 450000 N N 319 100 1000 149000 No growth  2:00(120) S 7080   Clot 
12 4 F PRE B ALL completed 1500  29000 N Y 909 1984 3100 316000  No growth 1:50(110)  60    
13 1 F Pre B ALL thrombosis 2500  138000 N Y 34 221 1300 16000   2:00(120) S 550 3.5 completed  
14 10 M Leukemia completed 8200  157000 N Y 254 5256 7300 359000   2:00(120) S 2581    
15 2 M Pre B ALL completed 1200  22000 N Y 1074 3150 5000 313000   1:30(90) S 84 4.9   
16 5 M Osteosarcoma  13800  342000 N N 1461      1:50(110) S 8556 4.2 palliative care  
17 4 F 
metastatic 
neuroblastoma completed 3800 15.3 485000 N Y 208 4225 5700    2:15(135) J 2508   1.23 
18 11 M Osteosarcoma completed 4500  172000 N N 308 2760 4600 167000   2:20(140)  2655 4.6   
19 5 M Pre B ALL  13900 12.8 27000 N Y 738      1:45(105) J 1740  don’t know 1.02 
20 3 M Pre B ALL completed 1000 14 8000 No growth Y 883 3332 4900 312000   1:20(80) J 120   1.12 
21 2 F 
metastatic 
neuroblastoma   7200 13.2 218000 No growth N 225      2:15(135) J 8264  don’t know 1.15 
22 10 M Ewing's sarcoma  32600  162000 N N 86      1:45(105) S 15984  death  
23 2 F Pre B ALL infection 3200 10.2 225000 N N 118 5668 10900 245000 No growth No growth 2:00(120) S 1472 4.6 completed 1.03 
24 1 M Medulloblastoma thrombosis 7000  284000 N N 332 2300 5000 269000   2:15(135) S 3481  completed  
25 4 M 
RMS OF URINARY 
BLADDER infection 11700 10.6 239000 N N 134 399 2100 177000 candida  2:10(130) S 6084 6 completed 0.92 
26 2 M Pre B ALL Completed 2600 12.5 18000 N Y 674 40 1000 193000 No growth  1:40(100) S 89   1.08 
27 1 F AML completed 92500 12.8 44000 N Y 168 
Not 
done 1800 3000   1:40(100) J 4274 4.3  1.09 
28 2 F Pre B ALL 
neck 
broken+comp 4400 11.5 34000 No growth Y 981 5586 14700 292000   1:30(90) S 623   1 
29 6 M 
metastatic 
neuroblastoma infection 7600 13.4 676000 No growth N 50 6 600 8000 
gram 
negative   1:25(85) S 5092  completed 1.16 
30 4 F Pre B ALL completed 2700 13.8 167000 No growth Y 510 1568 2800 370000   1:45(105) J 1809 4.4  1.31 
31 4 M Pre B ALL Completed 8100 12.3 354000 N N 1129 4656 9700 190000   1:35(95) J 3969   1.07 
32 4 M Pre B ALL completed 1600 12.6 11000 No growth Y 1007 2160 5400 244000   1:40(100) S 32   1.1 
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33 4 F Pre B ALL infection 2000  10000 
candida 
tropicalis  Y 75 10 500 31000 candida  2:15(135) S 576 2.5 completed  
34 6 M Pre B ALL completed 2600 11.6 8000 No growth Y 1171 2950 5900 268000   1:45(105) S 130 4  1.01 
35 14 M Osteosarcoma completed+sepsis 16800 15.5 767000 No growth N 225 490 1400 105000 enterococcus  2:10(130) S 13776 1.3  1.38 
36 2 F Pre B ALL completed 3900 12.4 89000 No growth Y 1071 5040 8400 307000   2:15(135) S 1755 3.7  1.13 
37 4 M Pre B ALL Completed 3600 9.9 29000 No growth Y 952 3080 4000 188000   2:05(125)  936 4.3  0.92 
38 6 month M Pre B ALL infection 1900 11.2 56000 N Y 265 
not 
done 200 189000  
Enterobacter 
R 2:30(150) S 342 3.7 completed 1.02 
39 5 M Pre B ALL completed 1300 9.9 7000 No growth Y 524 2107 4300 150000   1:45(105) S 13   0.92 
40 9 F AML infection 1500 13 11000 No growth Y 80 
Not 
done 200 9000 E coli E Coli 1:40(100)  15 4 completed 1.22 
41 2 M Pre B ALL Completed 4600 11.9 35000 N Y 1180 4272 4600 203000   2:00(120) S 230 4.2  1.03 
42 4 M Pre B ALL Completed 22800 11.2 21000 No growth Y 980 4060 7100 156000   1:50(110)  4799 3.2  1.05 
43 3 month F PNET  8900 10.7 762000 contaminants N 186      1:00(60)  3738  death 0.97 
44 4 F Pre B ALL completed 3800 11.3 156000 N Y 917 1092 2600 216000   1:30(90) S 1216 5  1.02 
45 10 F AML  5300 9.2 21000 No growth Y 28      1:15(75) S 636 4.1 death 0.86 
46 1 M Pre B ALL  6800 10.5 27000 No growth Y 4      2:20(140) S 204 4.1 
don’t know 
referred 0.97 
47 2 M Pre B ALL infection 7400 10.4 363000 No growth N 206 30 1000 161000  
Staph. 
Aureus S 1:50(110) S 1776 4.2 completed 0.97 
48 2 F Pre B ALL completed 5100 13 51000 No growth Y 276 2482 3400 384000   2:15(135) S 771   1.22 
49 13 F lymphoma  7200 13.2 218000 No growth N 717      1:45(105) S 6264  don’t know 1.15 
50 12 F AML completed 5000 13.1 42000 No growth Y 203 2750 5000 217000   1:55(115) S 224   1.22 
51 3 F AML hematoma 3700 11.8 12000 N Y 14 10 500 4000   1:50(110) S 740  
death on 
28/03/2011 1.1 
52 3 M AML infection 11900 9.8 363000 N N 199 
Not 
done 200 11000  enterobacter 1:45(105) S 2975 4.5 
death 
on13/09/2011 0.88 
53 2 F AML completed 65300 11.5 197000 N Y 159 56 800 85000  No growth 1:30(90) S 4963 2.9  1.06 
54 13 M AML  36000  18000 N Y 349      1:50(110) S 18360 4.4 completed  
55 8month M Neuroblastoma completed 15400  713000 No growth N 183 2640 5500 234000   1:35(95) S 12012 4.6   
56 2 M ALL completed 28200 10.8 82000 No growth Y 637 4557 9300 328000  
Coagulase 
neg   1574   0.93 
57 2 M 
clear cell sarcoma R 
kidney completed 11800  337000 N N 245 352 2200 180000   2:15(135) S 3540    
58 15 F Hodgkin lymphoma completed 14800 12 410000 No growth N 652 2475 5500 192000   1:50(110) S 13172 3.2  1.09 
59 1 F LCH X completed 9000 9.3 315000 No growth N 477 6760 8700 360000  Enterococcus 2:05(125) J 5220   0.87 
60 6 F ALL  4600 11.3 54000 No growth Y 949      2:20(140) S 743  still going on 1.02 
61 6 F ALL  10700 10.8 22000 No growth Y 950      1:20(80) S 163  still going on 0.93 
62 7 M ALL  1000 10.2 59000 N Y 950      1:15(75) S 60  still going on 0.95 
63 2 M Acute Leukemia completed 15000 12.4 46000 N Y 140 18 900 14000   1:45(105) J 2414   1.13 
64 5 M Pre B ALL  2400 11.5 26000 No growth Y 851      1:40(100)  145  still going on 1.06 
65 13 F ALl  4600 10.4 56000 No growth Y 54      2:05(125) S 1556 4.1 death 0.97 
66 3 M T cell ALL infection 3100 18.6 424000 No growth Y 403 1364 3100 396000  Pseudomonas 1:45(105)  776 4.6 don’t know 1.72 
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67 3 M Neuroblastoma  9500 11.1 469000 No growth N 566      1:30(90) S 3705  don’t know 1.01 
68 2 M ALL completed 1100 11 10000 No growth Y 201 56 2800 9000  No growth 1:50(110) S 23 4.4  1 
69 4 M Lymphoma completed 8100  499000 N N 328 2409 7300 324000   1:30(90) S 4374    
70 1 f 
metastatic 
neuroblastoma  10700 11.1 471000 No growth Y 752       S 6099 4.8 dint complete 1.01 
71 2 M Pre B ALL  1200  24000 No growth Y 226      1:15(75) S 12  death  
72 1 F ALL  2100 10 19000 No growth Y 810      1:05(65) S 105 3.5 still going on 0.93 
73 1 F ALL  1600 10.5 88000 No growth Y 810      2:00(120) S 226  still going on 0.97 
74 7 M Pre B ALL  3300 11.7 18000 No growth Y 167      1:05(65) J 627  death 1.06 
75 6month M Hepatoblastoma  13900  887000 N N 7      1:45(105) J 5282 4 don’t know  
76 3 M ALL  22800 9.8 49000 No growth Y 1055      2:10(130) S 16416  still going on 0.88 
77 8 M Hepatoblastoma completed 7800 10.3 305000 N N 511 4142 10900 32500   1:45(105) S 2730   0.96 
78 8 M ALL  4000 10.5 367000 N N 524      1:20(80) S 1280 4.7 don’t know 0.97 
79 3 M Pre B ALL  2500  174000 No growth Y 1042      2:15(135) J 1625 4.7 still going on  
80 11 M AML infection 15900 12.2 13000 N Y 65 0 400 17000  E Coli 1:45(105) J 1479  don’t know 1.1 
81 11month M AML completed 10200 12.1 17000 No growth Y 442 
Not 
done 100 9000  No growth 1:30(90) J 408 4.5  1.13 
82 11 M ALL  600 clot 22000 No growth Y 1000      2:00(120) J 12 3.2 still going on Clot 
83 7 F ALL  7900 10.5 93000 N Y 190      1:50(110) J 1933 4.1 death 0.97 
84 10 M Burkitts lymphoma  14600 9.8 506000 No growth N 19       S 14016 3.8 
dis on 
request23/05/11 0.88 
85 3 F neuroblastoma   6200 10.4 295000 No growth Y 390      1:30(90) S 3906  don’t know 0.97 
86 1 F Pre B ALL  6100 11.4 8000 N Y 272      1:55(115) S 748  
don’t know 
referred 1.04 
87 1 M Acute leukemia  1900 10.9 28000 No growth Y 957      1:30(90) S 76 4.6 still going on 0.99 
88 6 month F 
clear cell sarcoma R 
kidney  28000 13.5 177000 N N 111      1:00(60) S 19600 3.7 don’t know 1.26 
89 9 M Pre B ALL  1900 10 14000 No growth Y 958      2:20(140) S 190  still going on 0.93 
90 2 F Pre B ALL Completed 4300 11.7 22000 N Y 795 2867 6100 161000   1:45(105) S 440   1.06 
91 3 M Leukemia  2200 10.7 35000 N Y 820      1:15(75) S 44  still going on 0.97 
92 7 M AML  6300 11.9 24000 No growth Y 185      1:45(105) S 252 3.6 don’t know 1.03 
93 1 M Pre B ALL completed 1200 10 22000 No growth Y 381 2914 9400 396000   1:50(110) S 84 4.6  0.93 
94 3 M T cell ALL  3000 11.9 227000 No growth Y 295      1:45(105) S 570 4.4 don’t know 1.06 
95 1 M 
Rhabdomyosarcoma 
L testis infection 8200 10.5 423000 N N 243 1056 3300 97000  E Coli 1:35(95) J 2296 4.2 completed 0.97 
96 9 F Pre B ALL  1400  40000 No growth Y 790      1:30(90) J 112 4.1 still going on  
97 1 M Acute Leukemia  38000 12.4 10700 No growth Y 26      1:55(115) J 7604 4.9 don’t know 1.08 
98 9 F Ewing's sarcoma completed 4100 11.1 95000 N Y 197 
Not 
done 300 45000   1:50(110) J 2460   1.01 
99 3 M Pre B ALL infection 2700  18000 N Y 8 460 2000 32000 No growth 
Staph. 
Aureus S 1:55(115) S 55  don’t know  
100 4 F AML Completed 2900  146000 contaminants Y 539 1564 2600 280000   1:40(100) S 551 4.1   
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101 10 M ALL  6700 12.4 23000 No growth Y 194      1:30(90) J 1216  death 1.13 
102 10 F Osteosarcoma  2700  309000 No growth Y 734      1:30(90) J 378  still going on  
103 8 M Burkitts lymphoma completed 9900  751000 No growth N 119 4472 8600 357000   1:35(95) S 7524    
104 3 F Pre B ALL  2600  150000 No growth Y 722      1:45(105) S 1534 4.3 still going on  
105 6 F ALL  2800 11.9 41000 No growth Y 722      2:00(120) J 281 4.3 still going on 1.03 
106 1 m r Lung GCT completed 4200 10.9 267000 No growth N 237 1235 6500 216000   2:00(120) S 1386   0.99 
107 12 F Pre B ALL  2600 11 493000 N N 243      2:05(125) J 1066 4.1 death 1 
108 4 F Pre B ALL  5300 9.4 157000 N N 680      1:21(81) J 2703 4.5 still going on 0.92 
109 4 M Pre B ALL  1800 11.8 64000 No growth Y 652      1:45(105) J 18  still going on 1.1 
110 2 F Pre B ALL infection 2700  217000 N Y 441 4028 5300 408000 
staph Coag 
neg  
Staph Coag 
neg 2:00(120) J 945  don’t know  
111 4 F Pre B ALL  1900 9.9 88000 N Y 608      1:35(95) J 190 4.5 still going on 0.9 
112 12 M Osteosarcoma completed 18200  491000 N N 217 494 2600 31000   1:45(105) J 12922    
113 9 M Osteosarcoma infection 11600 11.4 441000 N N 77 30 1500 35000  
candida 
tropicalis 0:55(55) J 7540  completed 1.04 
114 2 F Pre B ALL infection 4500 11.9 17000 No growth Y 246 48 1600 331000 candida 
candida 
tropicalis 2:00(120) S 360  completed 1.03 
115 2 M Hepatoblastoma dint complete 12700  351000 N N 106 1344 3200 203000   2:00(120) S 7620 4.1   
116 2 F Osteosarcoma Completed 7100  439000 N N 512 3726 5400 225000   1:30(90) S 2343    
117 2 F Pre B ALL  1300  66000 N Y 423      1:25(85) S 169  still going on  
118 2 F Leukemia  3200 11 53000 N Y 35      2:00(120) S 704  death 1 
119 5 M Leukemia  1500 12.2 31000 No growth Y 45      1:25(85) S 150 3.5 don’t know 1.1 
120 2 M Pre B ALL  2600  28000 N Y 518      1:20(80) S 286 4.8 still going on  
121 8 F Medulloblastoma completed 2800 11.2 355000 N Y 499 2115 4500 248000   1:25(85) S 2184   1.05 
122 14 M ALL  4300  179000 N N 510      1:40(100) S 1462 4.7 still going on  
123 17 F Osteosarcoma completed 7400  230000 N N 203 1116 3100 147000   1:30(90) S 4588    
124 6 M Pre B ALL  5200  311000 No growth N 496      1:35(95) J 2240 4 still going on  
125 4 M Pre B ALL  8100  43000 No growth Y 469      1:10(70) J 32 1.5 still going on  
126 13 F Pre B ALL infection 4600  43000 contaminants Y 27 27 900 51000 pseudomonas  1:10(70) J 2622  don’t know  
127 7 M T cell ALL  4200 11.1 475000 No growth N 11      0:40(40) J 3486 3.2 don’t know 1.02 
128 13 F Hodgkin lymphoma  9600 10.7 295000 No growth N 451      1:30(90) J 7296 2.6 
don’t know 
referred 0.97 
129 2 M Pre B ALL  3100 10.8 150000 No growth Y 440      1:15(75) J 775 3.9 still going on 0.93 
130 6 F Leukemia  5200  242000 N N 114      1:15(75) S 3016 4.6 death  
131 5 M Leukemia infection 1300 10.6 20000 No growth Y 27 2726 2900 95000  No growth 1:30(90) S 260  don’t know 0.92 
132 3 M AML  15300 13 13000 No growth Y 21      1:30(90) J 612 2.6 death 1.22 
133 7 M Pre B ALL  1100 12.1 68000 No growth Y 413      1:30(90) J 33 4 still going on 1.13 
134 12 M Pre B ALL  2800 10.9 26000 No growth Y 413      1:25(85) J 756 3.8 still going on 0.99 
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135 10 F PNET  6400  228000 N N 398      1:45(105) J 3008 4.2 still going on  
136 7 M Pre B ALL  2600 12.4 13000 No growth Y 7      1:45(105) J 79 3.9 death 1.13 
137 11 M T cell ALL  500 10.2 16000 No growth Y 398      1:50(110) J N  still going on 0.95 
138 1 M AML completed 6000  452000 N Y 287 1162 8300 288000 No growth  1:55(115) J 2580 4.4   
139 3 M ALL completed 5500 10.8 333000 No growth N 273 2376 3600 199000  No growth 1:20(80) J 1430 4.2  0.93 
140 9 M Neuroblastoma thrombosis 6000 11.6 319000 No growth Y 280 24 800 87000 No growth  1:20(80) J 2280 4 completed 1.01 
141 9month F ALL  3400  8000 No growth Y 726      1:10(70) J 102 3.6 still going on  
142 10 M Osteosarcoma completed 2000  205000 No growth Y 454 3528 7200 206000   1:55(115) J 40    
143 7 F ALL  1600 11.9 65000 No growth Y 713      1:40(100) J 704  still going on 1.06 
144 1 M ALL  1600 11 63000 No growth Y 698      1:25(85) J 32 5.1 still going on 1 
145 1 F Neuroblastoma completed 13400 10.7 429000 N N 77 1680 4800 147000   1:45(105) J 5330 5.2  0.97 
146 3 F Pre B ALL  3400  6000 N Y 629      1:45(105) J 35  still going on  
147 6 F ALL  2000 12.3 8000 No growth Y 628      1:45(105) J 22 3.7 still going on 1.07 
148 1 M Neuroblastoma  15700 10 359000 N N 614      1:40(100) J 6751 3.7 still going on 0.93 
149 6 M Pre B ALL  3100 11 73000 No growth Y 600      1:40(100) J 372  still going on 1 
150 5 M Pre B ALL  5200  425000 No growth N 600      1:30(90) J 2704  still going on  
151 5 M ALL Extravasation 2200  15000 No growth Y 476 126 1400 224000 No growth  1:55(115) J 176  completed  
152 5 M 
Embryonal sarcoma-
liver completed 14600 12.5 351000 N N 365 3630 6600 229000   1:45(105) J 12410 2  1.08 
153 15 F Osteosarcoma infection 2100  113000 N Y 231 8058 10200 63000  Aspergillus  J 105  
death on 
2/04/2013  
154 10 M  lymphoma  16800 13.2 407000 No growth N 182      2:00(120) J 11760  don’t know 1.21 
155 21days M Lymphoma  2100  50000 No growth Y 46      1:45(105) J 44  death  
156 6 F 
metastatic 
neuroblastoma  2100 10.5 195000 No growth Y 490      1:15(75) J 756  still going on 0.97 
157 3 M ALL  2500  59000 No growth Y 490      1:30(90) J 125 4.3 still going on  
158 3 M Pre B ALL completed 3400 12.2 21000 N Y 189 2912 5200 155000 contaminants  1:45(105) J 374   1.1 
159 4 M AML completed 15300  38000 N Y 206 1419 4300 289000   1:40(100) J 1580    
160 11 M Lymphoma Completed 17500 12.4 372000 No growth Y 336 3710 5300 194000    J 2625 2.8  1.13 
161 4 M 
metastatic 
neuroblastoma completed 8900 11.7 472000 No growth N 189 8284 10900 244000   1:40(100) J 5607 2.3  1.06 
162 4 M EMS nasal cavity  3500 11.5 1010000 No growth Y 431      1:30(90) J 350  still going on 1.06 
163 6 M 
metastatic 
neuroblastoma Completed 8900 12.4 343000 No growth N 228 2809 5300 247000   1:45(105) J 5963   1.13 
164 9 month F Pre B ALL Completed 7800  140000 No growth N 308 1026 2700 295000   1:30(90) J 3042    
165 12 F T cell ALL  11100 11.9 260000 No growth N 363      1:40(100) J 9435  still going on 1.03 
166 7 month M AML  4700 15.1 48000 No growth Y 356      1:50(110) S 94 3.7 still going on 1.37 
167 10 M Pre B ALL  3400 10.1 131000 No growth Y 356      1:55(115) J 1191  still going on 0.93 
168 1 M Acute leukemia infection 101000 11.4 370900 N N 31 220 2200  MRSA MRSA 1:45(105) J 4939 4.4 completed 1.04 
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169 8 M Neuroblastoma infection 11500 13.5 408000 N Y 87 312 5200 6000 No growth No growth 1:25(85) J 3335 3.8 still going on 1.23 
170 4 M Pre B ALL  1800 11.9 19000 No growth Y 5      00:45(45) J 18 3.6 
don’t know 
referred 1.06 
171 1 M Pre B ALL  2800 11.8 10000 N Y 314      1:45(105) S 168 3.9 still going on 1.1 
172 6 M Lymphoma  17400  107000 No growth Y 314      00:50(50) S 2436  still going on  
173 13 M Osteosarcoma  8400  260000 No growth N 314      1:45(105) J 5292  still going on  
174 0 M Osteosarcoma Sepsis fungal 10500 11.1 229000 No growth Y 140 3498 6600 50000 Aspergillus  2:00(120) S 6195  
don’t know 
referred 1.02 
175 3 M Pre B ALL  1400 12.2 28000 No growth Y 300      1:30(90) J 70 4 still going on 1.1 
176 1 M ALL  6800 12.9 15000 No growth N 300      2:00(120) J 2788 4.6 still going on 1.18 
177 13 M Ewing's sarcoma  13500 11 251000 No growth N 259      1:30(90) J 3645  still going on 1 
178 3 M Pre B ALL  8500 11.2 26000 No growth Y 259      2:00(120) J 1275  still going on 1.05 
179 2 M Pre B ALL  4500 10.7 16000 No growth Y 259      1:15(75) J 1170 4.2 still going on 0.97 
180 1 M Pre B ALL  21700  35000 N Y 349      1:45(105) J 716 4 still going on  
181 2 M Ewing's sarcoma  10400 10.6 361000 No growth N 335      00:55(55) J 4160 3.9 still going on 0.96 
182 13 M Ewing's sarcoma  4000  214000 N N 335      1:15(75) J 1680  still going on  
183 8 M Pre B ALL  51000 13.2 23000 N Y 335      1:50(110) J 4508 3.9 still going on 1.21 
184 1 F RMS  16200  369000 N Y 308      1:10(70) J 3888  still going on  
185 5 F Pre B ALL  3300 11.2 64000 No growth Y 293      1:50(110) J 664  still going on 1.05 
186 2 M Wilm's completed 10100 11.7 533000 N Y 157 2310 7700 330000   1:40(100) J 3838   1.06 
187 4 M ALL  4300 12.4 15000 No growth Y 279      1:15(75) J 19 4.1 still going on 1.13 
188 7 M RMS  4500  306000 N Y 279      1:40(100) J 3105  still going on  
189 3 F Pre B ALL  2900 11 27000 No growth Y 279      1:40(100) J 116 3.1 still going on 1 
190 2 M Pre B ALL  2200 12.1 15000 No growth Y 265      1:15(75) J 0 4.5 still going on 1.13 
191 6month M Pre B ALL  5100 12.8 32000 No growth Y 244      1:15(75) S 421  still going on 1.09 
192 1 F Lymphoma Completed 11200 11.5 193000 No growth Y 229 3528 9800 259000   1:40(100) J 2576 4  1.06 
193 6 M ALL Completed 5200 11.9 352000 No growth N 1322 3060 6800 295000   1:45(105) S 3276   1.03 
194 4 M  Neuroblastoma Completed 13400  574000 No growth N 238 3102 6600 293000   1:45(105) J 7236    
195 5 F AML  5300  39000 No growth Y 223      1:30(90) J 106 4.2 still going on  
196 8 F ALL Completed 2700 12.3 257000 No growth Y 1140 2964 7900 277000   1:15(75) J 54   1.07 
197 9 M Pre B ALL Completed 1000 13.4 15000 No growth Y 1331 3600 7200 231000   1:45(105) S 20   1.16 
198 6 F ALL  17600 11.1 18000 N Y 209      1:40(100) S 299 3.8 still going on 1.01 
199 1 M Pre B ALL  2800 10.6 14000 No growth Y 202      1:15(75) J 451  still going on 0.92 
200 3 M Neuroblastoma  3300 11.2 103000 No growth Y 174      1:15(75) J 132  
don’t know 
referred 1.05 
201 15 F Pre B ALL  1300 10.8 22000 No growth Y 195      1:50(110) J 78 4.8 still going on 0.98 
202 2 F AML  24000 11.4 9000 contaminants Y 19      1:45(105) J 14880  death 1.04 
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203 3 M Pre B ALL  1100 11.4 38000 N Y 188      1:45(105) S 110 4.5 still going on 1.04 
204 3 F Neuroblastoma  6700 14.9 158000 N N 174      1:25(85) J 3953 4 still going on 1.35 
205 7 M Hodgkin lymphoma  18100 12 440000 No growth Y 160      1:45(105) J 14299 3.8 still going on 1.09 
206 3 F ALL infection 1700 12.7 15000 No growth Y 12 
Not 
done 200 10000  
Staph Coag 
Neg 1:30(90) J 17 3.5 
death on 
22/08/2013 1.16 
207 8 M T cell ALL  6100 14.1 15000 N Y 146      1:50(110) J 82 3.7 still going on 1.28 
208 2 M ALL  17800 11.4 20000 No growth Y 131      1:15(75) J 356 4.7 still going on 1.04 
209 1 M ALL  7000 13.6 32000 N Y 95      1:15(75) J 140  death 1.23 
210 9 F Lymphoma  10200 12 359000 No growth Y 132      1:15(75) J 6222 3.1 still going on 1.09 
211 4 F Rhabdoid tumour  8600 11.4 454000 N N 118      1:15(75) J 2752  still going on 1.04 
212 12 M Osteosarcoma  10000 11 10000 NFGNB Y 118      1:15(75) J 4700 4.5 still going on 1 
213 13 F T cell ALL  1500  247000 N Y 118      1:15(75) J 310 3.9 still going on  
214 1 F Pre B ALL  5300  91000 No growth Y 2      1:30(90) J 1166  
don’t know 
referred  
215 1 F neuroblastoma infection 18200  321000 N Y 150 
Not 
done 100 9000 No growth 
Coagulase 
neg 1:45(105) S 4186 4.4 still going on  
216 1 F AML  147100 10.8 78000 N Y 90      1:30(90) J 9143 4.5 still going on 0.93 
217 11 M Osteosarcoma  11600  325000 N N 76      1:20(80) J 4950  still going on  
218 7 M RMS  3100  394000 N Y 76      1:30(90) J 1674 4.2 still going on  
219 1 M Hepatoblastoma  11300 10.6 397000 N N 177      1:30(90) J 1808 4.5 still going on 0.92 
220 2 M Pre B ALL  500 12.8 76000 N Y 139      1:45(105) J 0  still going on 1.09 
221 4 F Pre B ALL  8800 11.5 12000 No growth Y 139      0:55(55) J 1441 4.3 still going on 1.06 
222 2 M Neuroblastoma  3500 11.7 93000 No growth Y 125      1:30(90) J 350 4.5 still going on 1.07 
223 3 F Pre B ALL  3900 12.4 21000 Diptheroids Y 125      1:25(85) J 123 4.5 still going on 1.13 
224 1 M Leukemia infection 3900 21.5 8000 
candida 
tropicalis  Y 23 520 2600 9000 MRSA MRSA 1:15(75) J 507 3.4 
don’t know 
referred 1.91 
225 8 F Pre B ALL completed 1600 13.9 39000 No growth Y 1183 3900 10000 2040000   1:20(80) S 176   1.21 
226 4 M Pre B ALL completed 2500 13.1 123000 No growth Y 1196 611 4700 358000   1:30(90) S 300   1.15 
227 6 F Neuroblastoma  9400 12.1 224000 N Y 83      1:00(60) J 8178 2.5 still going on 1.13 
228 11 M Hodgkin lymphoma  7100  571000 No growth Y 83      1:10(70) J 5112  still going on  
229 4 M Pre B ALL  2000 10.7 212000 No growth Y 70      1:15(75) S 800 4.4 still going on 0.97 
230 1 F Wilm's bilateral  16500 11.3 459000 
Coag Neg 
staph Y 70      1:15(75) S 13695 2.4 still going on 1.02 
231 6month M Hepatoblastoma  9700 10.9 424000 N Y 41      1:20(80) J 1261 4.3 still going on 0.99 
232 4 F ALL  600 10.7 16000 No growth Y 181      1:10(70) J 6 4.3 still going on 0.97 
233 2 M Ependymoma  5100 10.8 167000 N Y 48      1:30(90) J 1020  still going on 0.93 
234 6 M Lymphoma  9100 14.8 174000 N Y 46      1:15(75) J 6461  still going on 1.34 
235 3 F ALL  9600 11.8 191000 No growth Y 34      1:10(70) J 6912  still going on 1.1 
236 6 M  Lymphoma   4100 13.9 17000 No growth Y 34      1:05(65) J 902 3.7 still going on 1.21 
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237 3 F Pre B ALL  6500 11.5 161000 No growth Y 20      1:00(60) J 1430 3.6 still going on 1.06 
238 3 M EMS bladder  400 11.7 162000 No growth Y 20      0:50(50) J N 4.1 still going on 1.07 
239 7 M Pre B ALL completed 1300 12.8 113000 No growth Y 589 506 2200 263000   1:15(75) S 39 3  1.09 
 
 
 
